Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.

Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to soaring demand for its anti-inflammatory drug.

Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...

The chipmaker at the heart of the AI boom was one of the top performers in the S&P 500 Tuesday, helping push the index to an ...

A mum has opened up about her daughter’s eczema struggles, saying it was heartbreaking to see her baby’s sheets splattered ...

Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...

Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales(recorded by Sanofi) increased 27% ...